

## Phylogica granted US patent for peptides entering brain cells

**PERTH, Australia, 4<sup>th</sup> October 2017:** Phylogica Limited (ASX:PYC) (**Phylogica** or the **Company**), developer of a leading intracellular drug delivery platform technology, is pleased to announce it has been granted a further US patent (US 2014/0141452 A1) covering the identification of Phylomers with the ability to enter specific endothelial cells in the brain.

Delivering cargoes into the brain endothelial cells is a first step towards developing better medicines for neurological conditions of the central nervous system. Discovering and developing medicines that target the brain is significantly impeded by the blood brain barrier, and more specifically, by brain endothelial cells which are resistant to foreign molecules. We have now shown that brain endothelial cells are accessible to Phylogica's Phylomers and that these peptides could be candidates for delivering drug cargoes into the brain. The brain represents a large market with wide unmet need, which is expected to increase with an ageing population.

The identification of Phylomers with the potential to cross the blood brain barrier comes from the early work of Phylogica with then pharmaceutical partner Roche, and was a precursor to development of the Company's next generation Functional Penetrating Peptide (FPP) technology platform.

Commenting on the work, Phylogica's CEO Stephanie Unwin said, "Phylogica is developing a matrix of Phylomer classes that penetrate diverse cell types and carry different drug cargoes. Importantly, many of the Phylomers described here showed significant specificity for brain endothelial cells, which raises two interesting points. First, cell specificity is important because it potentially reduces dosing requirements and toxicity. And second, by combining a cell-specific FPP with a cargo that enables gene editing or that binds a disease target, it may be possible to develop very effective disease-specific therapies. In the near term, The Company will continue to assess the properties of these patented Phylomers for further validation of cell penetration and cargo delivery."

ENDS

For further information, please contact:

#### INVESTORS

Stephanie Unwin  
CEO  
[stephanieu@phylogica.com](mailto:stephanieu@phylogica.com)  
0411 132 287

#### MEDIA

Ben Walsh  
WE Buchan  
[bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)  
0411 520 012

### About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a Phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and Genentech.

### Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

[www.phylogica.com](http://www.phylogica.com) ABN 48 098 391 96